Acute Myeloid Leukemia: Reviewing Current Best Practice and Exploring Novel Paradigms Ahead
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with AML.
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
Target Audience
This educational program is intended for physicians, PAs, nurses, pharmacists, and other healthcare professionals who care for patients with AML.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Characterize the pathophysiologic, clinical, cytogenetic, and molecular profiles that guide therapy selection for patients with AML
- Plan evidence-based therapeutic strategies for older patients, those with comorbidities, and/or those with secondary AML, using novel targeted agents or formulations and refinements of conventional chemotherapy
- Select optimal maintenance treatment following induction therapy for patients who are not candidates for, or who choose not to proceed to, hematopoietic stem cell transplantation
- Develop personalized treatment plans for therapeutically targetable molecular subsets of AML
- Discuss promising novel agents in clinical development for the treatment of AML
Daniel Pollyea, MD, MS
Professor of Medicine
Clinical Director of Leukemia Services
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado
Courtney DiNardo, MD, MSCE
Associate Professor
Division of Cancer Medicine
Department of Leukemia
UT MD Anderson Cancer Center
Houston, Texas
Eytan M. Stein, MD
Associate Attending Physician
Director, Program for Drug Development in Leukemia Service
Department of Medicine
Memorial Sloan Kettering
Cancer Center
New York, New York
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Courtney DiNardo, MD, MSCE
Abbvie, Inc.: Consultant/Advisor/Speaker
Astellas Pharma US, Inc.: Consultant/Advisor/Speaker
Bristol-Myers Squibb Company: Consultant/Advisor/Speaker
Genmab A/S: Consultant/Advisor/Speaker
GlaxoSmithKline: Consultant/Advisor/Speaker
Jazz Pharmaceuticals Inc.: Consultant/Advisor/Speaker
Novartis Pharmaceuticals Corporation: Consultant/Advisor/Speaker
Servier Pharmaceuticals LLC: Consultant/Advisor/Speaker
Daniel Pollyea, MD, MS
Abbvie, Inc.: Consultant/Advisor/Speaker; Grant/Research Support
Aptevo Therapeutics Inc.: Data and Safety Monitoring Board
Arcellx: Consultant/Advisor/Speaker
AstraZeneca Pharmaceuticals LP: Consultant/Advisor/Speaker
BeiGene: Consultant/Advisor/Speaker
BerGenBio ASA: Consultant/Advisor/Speaker
Bristol-Myers Squibb Company: Consultant/Advisor/Speaker; Grant/Research Support
Genentech, Inc.: Consultant/Advisor/Speaker
GlycoMimetics, Inc.: Data and Safety Monitoring Board
HiberCell Inc.: Consultant/Advisor/Speaker
ImmunoGen, Inc.: Consultant/Advisor/Speaker
Jazz Pharmaceuticals Inc.: Consultant/Advisor/Speaker
Karyopharm Therapeutics: Grant/Research Support
Kura Oncology, Inc.: Consultant/Advisor/Speaker
LINK: Consultant/Advisor/Speaker
Magenta Therapeutics: Consultant/Advisor/Speaker
Medivir AB: Consultant/Advisor/Speaker
Novartis Pharmaceuticals Corporation: Consultant/Advisor/Speaker
Qihan Biotech: Consultant/Advisor/Speaker
Ryvu Therapeutics: Consultant/Advisor/Speaker
Syros Pharmaceuticals: Consultant/Advisor/Speaker
Teva Pharmaceutical Industries Ltd: Grant/Research Support
Zentalis Pharmaceuticals: Consultant/Advisor/Speaker
Eytan M. Stein, MD
Abbvie, Inc.: Consultant/Advisor/Speaker
Agios, Inc.: Consultant/Advisor/Speaker
Aptose Biosciences Inc.: Consultant/Advisor/Speaker
Astellas Pharma US, Inc.: Consultant/Advisor/Speaker
Auron Therapeutics: Stock/Stock Options
Blueprint Medicines: Consultant/Advisor/Speaker
Bristol-Myers Squibb Company: Consultant/Advisor/Speaker; Grant/Research Support
Calithera Biosciences, Inc.: Consultant/Advisor/Speaker
Cellectis SA: Data and Safety Monitoring Board
CTI BioPharma Corp.: Consultant/Advisor/Speaker
Daiichi-Sankyo Co.: Consultant/Advisor/Speaker
Eisai Inc.: Grant/Research Support
Epizyme: Data and Safety Monitoring Board
Foghorn Therapeutics: Consultant/Advisor/Speaker
Genentech, Inc.: Consultant/Advisor/Speaker
Genesis Therapeutics: Consultant/Advisor/Speaker
Gilead Sciences, Inc.: Consultant/Advisor/Speaker
Janssen Pharmaceutica Products, LP: Consultant/Advisor/Speaker
Jazz Pharmaceuticals Inc.: Consultant/Advisor/Speaker
Kura Oncology, Inc.: Consultant/Advisor/Speaker
Menarini Group: Consultant/Advisor/Speaker
Neoleukin Therapeutics, Inc.: Consultant/Advisor/Speaker
Novartis Pharmaceuticals Corporation: Consultant/Advisor/Speaker
OnCusp Therapeuics: Consultant/Advisor/Speaker
Ono Pharmaceutical Co., Ltd.: Consultant/Advisor/Speaker
PinotBio, Inc.: Consultant/Advisor/Speaker
Servier Pharmaceuticals LLC: Consultant/Advisor/Speaker
Syndax Pharmaceuticals Inc.: Consultant/Advisor/Speaker
Syros: Consultant/Advisor/Speaker
NCCN and CCO Staff Disclosures
None of the planners/managers for this educational activity has relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 2.0 contact hours.
Pharmacists
NCCN designates this application-based continuing education activity for 2.0 contact hours (0.2 CEUs) of continuing education credit. UAN: JA4008196-0000-22-136-H01-P
PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. Approval is valid until December 22, 2023. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 2.00 AAPA Category 1 CME credit
- 2.00 ACPE contact hours
- 2.00 AMA PRA Category 1 Credit™
- 2.00 ANCC contact hours
- 2.00 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing